. Author manuscript; available in PMC: 2015 Aug 13.

Published in final edited form as: Cochrane Database Syst Rev. 2014 Aug 13;8:CD003256. doi: 10.1002/14651858.CD003256.pub2

Comparison 6. Liposomal daunorubicin versus ABV (RCT).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Progression of KS	1	227	Risk Ratio (M-H, Fixed, 95% CI)	0.78 [0.34, 1.82]
2 Clinical response	1		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
2.1 Complete response	1	227	Risk Ratio (M-H, Fixed, 95% CI)	2.87 [0.30, 27.19]
2.2 Partial response	1	227	Risk Ratio (M-H, Fixed, 95% CI)	0.83 [0.53, 1.31]
2.3 Overall response	1	227	Risk Ratio (M-H, Fixed, 95% CI)	0.90 [0.58, 1.38]
2.4 Stable disease	1	227	Risk Ratio (M-H, Fixed, 95% CI)	1.08 [0.87, 1.33]
3 Adverse events	1	227	Risk Ratio (M-H, Fixed, 95% CI)	1.01 [0.96, 1.06]